Bio-PrecisionAI Health

10/28/2026

Training Generative AI on Thousands of Drug Targets vs. One Target: Which Approach Generalizes Better?

Should we train a generative AI model to design molecules for thousands of protein targets or build a specialized model for one specific target?

This is a fundamental question in AI-driven drug discovery. The answer depends on what we mean by generalization, how much data are available, and what the model is expected to design.

1. Multi-Target Training: Learning Across Biological Targets

A multi-target model learns from protein–ligand data spanning many different targets.

Potential advantages:

• Learns shared patterns in molecular chemistry and protein–ligand interactions.
• Can transfer useful representations across related targets.
• May support drug design for previously unseen targets when supplied with appropriate target information.
• Reduces dependence on building a separate model for every protein.

The bottleneck: Training data are highly imbalanced. A few well-studied targets may have thousands of known ligands, while many others have very few experimentally characterized compounds.

The model may consequently favor familiar target families and chemical scaffolds rather than generalize equally well across biological space.

2. Single-Target Training: Specialization for One Protein

A single-target model focuses on one protein and its associated chemical data.

Potential advantages:

• Can concentrate on target-specific binding interactions.
• May be easier to optimize for a defined discovery campaign.
• Can incorporate target-specific experimental results through iterative refinement.

The bottleneck: High-quality active-compound data may be scarce, especially for novel or poorly studied targets. A model can overfit known chemical series, repeatedly generate close analogues, or struggle to propose genuinely novel compounds.

Its learned target-specific behavior also does not automatically transfer to other proteins.

3. Which Is More Generalizable?

Multi-target pretraining followed by target-specific adaptation is a compelling strategy to investigate, especially when target-specific data are limited.

A model can first learn broad chemical and biological representations from diverse datasets, then adapt to the target of interest using available structural, biochemical, and activity data.

However, success depends on the quality and diversity of the training data, the target representation, and how effectively the model distinguishes one target’s requirements from another’s.

More targets do not automatically mean better generalization. Thousands of redundant or poorly annotated targets may contribute less than a smaller, carefully curated and diverse dataset.

4. The Data Limitations That Matter Most

• Sparse activity data: Many proteins have few confirmed active ligands.

• Target imbalance: Well-studied families can dominate training.

• Assay heterogeneity: Activity measurements may differ across laboratories, experimental conditions, and assay types.

• Chemical redundancy: Large datasets can contain many related compounds without equivalent diversity in chemical space.

Target leakage: Similar proteins, related compounds, or duplicated structures across training and test sets can inflate apparent performance.

Distribution shift: Performance can deteriorate on unseen protein families, novel binding pockets, or unfamiliar molecular scaffolds.

💡 The key takeaway: Multi-target models offer the opportunity to learn transferable knowledge; single-target models offer focused optimization. The most useful architecture may combine both but its generalizability must be demonstrated through rigorous, leakage-resistant testing.

The ultimate question is not how many targets a model has seen. It is whether the model can generate novel, chemically feasible, target-relevant molecules that stand up to experimental validation.

10/28/2026

GenAI Conditioning vs. Cheminformatics-Based Property Prediction: Which Is Better for Drug Design?

Should we guide generative AI to create molecules with desired physicochemical properties from the start or generate molecules first and then evaluate them using cheminformatics tools?

This is an important design decision in AI-driven drug discovery. And my argument is that neither approach should work in isolation. A hybrid workflow is often the most practical starting point.

Approach 1: Physicochemical Property Conditioning

Here, desired molecular properties are incorporated into the generation process.

For example, a model may be guided toward molecules with a target molecular weight, lipophilicity, or topological polar surface area.

The advantage: Property objectives can influence which molecules the model generates, potentially reducing the number of unsuitable candidates.

The limitation: Conditioning does not guarantee that a molecule will satisfy the requested properties when independently evaluated or that it will be chemically feasible, synthesizable, or biologically active.

Approach 2: Generate First, Predict Properties Later

Here, a generative model produces candidate molecules, which are then evaluated using cheminformatics tools such as RDKit descriptors, quantitative structure-property relationship (QSPR) models, and ADMET prediction platforms.

The advantage: The workflow is modular, easier to benchmark, and allows generated molecules to be assessed independently of the generation model.

The limitation: If the generator repeatedly produces unsuitable molecules, post-generation filtering can discard a large fraction of the library. Prediction models also have their own uncertainty and may perform poorly on unfamiliar chemical structures.

So, which would I choose?

For a practical early-stage workflow, I would start with generation followed by independent property evaluation, establish a reliable baseline, and then introduce property conditioning or iterative optimization where it demonstrably improves the results.

Why?

🔹 Independent evaluation provides a useful check against the generator’s own assumptions.

🔹 Baseline filtering helps reveal which properties the generator already handles well and where it struggles.

🔹 Conditioning can then be targeted toward specific weaknesses rather than added without evidence of benefit.

🔹 A feedback loop can repeatedly generate, evaluate, and refine candidates.

Likely workflow:

Generate → Predict properties → Apply chemical and drug-likeness filters → Assess uncertainty → Refine generation → Experimentally validate.

For target-focused drug discovery, this workflow can be extended to include binding-site compatibility, selectivity, synthetic feasibility, and relevant ADMET endpoints.

💡 The key insight: Property conditioning is a way to influence generation; cheminformatics prediction is a way to evaluate molecules. They solve related but different problems.

The real question is not which technique sounds more advanced. It is which workflow produces more chemically valid, diverse, synthesizable, and experimentally promising candidates under rigorous evaluation.

10/28/2026

Physicochemical Property Conditioning in Generative AI Drug Design: Can We Tell AI What Kind of Molecule to Create?

Imagine asking a generative AI model to design a molecule that is not only compatible with a biological target, but also has the right solubility, lipophilicity, molecular size, and permeability for a potential drug.

This is the promise of physicochemical property conditioning in generative AI-driven drug discovery.

Rather than generating molecules without explicit property goals and filtering them afterward, property-conditioned models use desired molecular characteristics to guide generation or optimization.

What properties can we condition on?

🔹 Molecular weight: Influence the size of the generated molecule.

🔹 Lipophilicity (LogP or LogD): Help balance interactions with lipid environments and aqueous solubility.

🔹 Aqueous solubility: Address a key consideration for formulation and biological testing.

🔹 Topological polar surface area (TPSA): Help guide polarity and potential permeability.

🔹 Hydrogen bond donors and acceptors: Influence molecular recognition and interactions with biological targets.

🔹 Permeability and pharmacokinetic properties: Guide designs toward desired absorption, distribution, and exposure characteristics.

How does conditioning work?

Depending on the model, desired properties can be incorporated through conditional inputs, learned representations, reward functions, or guidance during molecular generation. Some workflows also use property predictors to rank and optimize generated candidates.

But there is a critical distinction: conditioning a model on a property does not guarantee that the generated molecule will achieve that property experimentally.

The current bottlenecks

1. The data problem

Reliable experimental property measurements are unevenly distributed across chemical space. Inconsistent assays, limited datasets, and noisy labels can weaken property predictions and conditioning.

2. The multi-objective trade-off

Optimizing one property can damage another. Increasing lipophilicity, for example, may improve some interactions while reducing aqueous solubility. Drug design requires balancing several competing objectives.

3. The gap between predicted and experimental properties

A model may generate a molecule with favorable predicted properties, yet experimental measurements can differ because of molecular behavior, assay conditions, or limitations in the prediction model.

4. Chemical validity and synthesizability

A molecule can satisfy numerical property constraints and still be chemically implausible, unstable, difficult to synthesize, or unsuitable for further development.

5. Biological relevance

Meeting physicochemical targets does not guarantee binding affinity, selectivity, cellular activity, or therapeutic efficacy. Property conditioning must ultimately connect to the biological target and intended use.

6. Benchmarking and generalization

A model can perform well on familiar compounds but struggle with genuinely novel chemical structures. Robust evaluation requires careful data splitting, uncertainty assessment, and prospective experimental validation.

💡 Where does the field need to go next?

The opportunity is to build models that jointly consider molecular structure, protein-pocket compatibility, physicochemical properties, synthetic feasibility, and ADMET characteristics while explicitly managing uncertainty and competing objectives.

The goal is not simply to generate molecules that satisfy a list of numerical constraints. It is to generate chemically feasible, biologically relevant candidates with a realistic path toward experimental validation.

10/28/2026

Boltz-2: Beyond Predicting Protein Structures to Predicting Drug–Target Binding Affinity

What if an AI model could do more than predict how a protein and a drug molecule fit together?

What if it could also estimate how strongly they bind?

That is one of the major advances introduced by Boltz-2, an open-source biomolecular foundation model developed by researchers associated with MIT and Recursion.

Unlike models focused primarily on predicting molecular structures, Boltz-2 combines 3D complex structure prediction with a dedicated binding-affinity prediction module.

What makes Boltz-2 particularly interesting?

1. Binding-affinity prediction

Boltz-2 estimates small-molecule–protein binding affinity, helping researchers prioritize compounds during hit discovery and lead optimization.

2. Pocket and contact conditioning

Researchers can provide distance constraints to guide predicted molecular interactions. This makes it possible to incorporate prior knowledge about a binding pocket or specific contacts into structure prediction.

3. Template conditioning

Known structures of related complexes can guide predictions, including templates containing multiple interacting chains.

4. Physics-based steering

The Boltz family also incorporates approaches that use physical potentials to improve structural plausibility, helping address issues such as steric clashes and incorrect stereochemistry.

5. Faster computational screening

In the reported FEP benchmark, Boltz-2 achieved a Pearson correlation of approximately 0.62, comparable to the evaluated free-energy perturbation approach, while being reported as more than 1,000 times faster.

💡 Why does this matter?

Drug discovery teams must evaluate enormous numbers of potential compounds. Combining structural predictions, affinity estimates, and controllable modeling could help researchers prioritize candidates before committing to expensive laboratory experiments.

However, predicted affinity is not proof of experimental binding, and strong binding does not automatically mean a molecule will be safe or effective in patients. Experimental validation remains essential.

The bigger picture: The future of AI-driven drug discovery is not simply predicting protein structures. It is connecting molecular structure, chemical interactions, and binding affinity to make better-informed decisions about which drug candidates to test.

10/28/2026

Sequence-Level vs. Residue-Level vs. Atom-Level Drug Design

How does AI move from understanding a protein’s amino acid sequence to designing a potential drug molecule that interacts with it?

It helps to understand three levels of molecular representation.

1. Sequence-Level Modeling

At this level, a protein is represented as a sequence of amino acids.

For example, a protein sequence might be represented as:

MKT...GAV

AI models can learn patterns in amino acid sequences to predict protein properties, identify potential targets, and support protein structure prediction or sequence-based design.

The focus: What can we learn from the order and identity of amino acids?

2. Residue-Level Modeling

At this level, amino acids are represented as residues, often with structural information such as their positions in 3D space, contacts, or interactions with neighboring residues.

This representation can help identify binding pockets, understand protein–ligand interactions, and guide protein modeling or design.

The focus: How do amino acid residues interact and organize within a protein’s structure?

3. Atom-Level Modeling

At this level, individual atoms and their spatial arrangements are represented explicitly.

Models can account for chemical bonds, molecular geometry, hydrogen bonding, electrostatic interactions, and steric constraints.

This detail is particularly valuable for molecular docking, ligand optimization, and atomistic simulations.

The focus: How do individual atoms determine molecular structure and interactions?

💡 Why does this distinction matter?

Each level provides a different view of the molecular system:

Sequence level → amino acid or nucleotide identity and order.

Residue level → protein organization and residue interactions.

Atom level → detailed molecular geometry and chemical interactions.

Where does AI fit in?

Different AI architectures operate at different levels, and some combine them. For example, a model may use protein sequence information to predict a structure, identify a binding pocket from that structure, and then generate or optimize a ligand at the atomic level.

These levels are complementary, not competing approaches. The appropriate representation depends on the task, and computational predictions still require experimental validation.

The big picture: Understanding how sequence, structure, and atomic interactions connect is central to modern computational drug discovery.

10/28/2026

Physics-Based Drug Design: Bringing the Laws of Nature into Drug Discovery

What if we could use the fundamental principles of physics to understand how a drug molecule interacts with its biological target and use that knowledge to design better medicines?

That is the power of physics-based drug design.

Unlike approaches that rely primarily on statistical patterns or learned predictions, physics-based methods use principles such as molecular mechanics, electrostatics, thermodynamics, and statistical mechanics to model molecular behavior and interactions.

How does it work?

🔹 1. Molecular interactions: Model the forces between a potential drug molecule and its target protein.

🔹 2. Molecular docking and scoring: Explore possible binding poses and estimate how favorably a molecule may interact with a binding pocket.

🔹 3. Molecular dynamics simulations: Simulate molecular motion to investigate how a drug–protein complex behaves over time.

🔹 4. Binding free-energy calculations: Estimate the thermodynamic favorability of binding to help compare candidate molecules.

🔹 5. Lead optimization: Use structural and energetic insights to guide chemical modifications that may improve binding affinity and selectivity.

💡 Why does it matter?

A molecule may fit inside a protein’s binding pocket, but shape alone does not determine whether it binds strongly or selectively.

Hydrogen bonding, electrostatic interactions, hydrophobic effects, molecular flexibility, solvent behavior, and entropy can all influence binding.

Physics-based approaches help researchers investigate these factors and understand why one molecular design might perform better than another.

What about AI?

The future lies in combining physics-based methods with artificial intelligence. AI can rapidly propose molecules and predict properties, while physics-based calculations can help evaluate molecular interactions and refine promising candidates.

However, these calculations have limitations, and their predictions depend on the models, assumptions, and sampling methods used. Experimental validation remains essential.

The big picture: Drug discovery is not just about finding molecules that look promising. It is about understanding the molecular interactions that could make them work.

By combining physics, chemistry, structural biology, and AI, we can build more informed strategies for designing tomorrow’s medicines.

10/28/2026

Pocket Conditioning: Guiding AI to Design Better Drug Candidates

What if we could guide AI to generate drug molecules that fit a protein’s binding pocket from the very beginning?

That is the idea behind pocket-conditioned drug design.

In structure-based drug discovery, a protein’s binding pocket provides important information about the shape, chemical environment, and interactions a potential drug must accommodate.

Pocket conditioning uses this information to guide computational models, particularly generative AI models toward designing molecules suited to a specific target pocket.

How does it work?

🔹 1. Define the target pocket: Identify the binding site on the protein structure.

🔹 2. Condition the model: Provide information about the pocket, such as its 3D geometry and chemical environment.

🔹 3. Generate candidate molecules: Use the pocket information to guide the generation of potential ligands.

🔹 4. Evaluate and optimize: Assess candidates for binding poses, chemical validity, synthesizability, selectivity, and drug-like properties.

💡 Why does it matter?

Instead of generating molecules without considering a specific binding site, pocket-conditioned approaches can incorporate structural information into the design process, helping researchers explore candidates tailored to a particular protein target.

However, a molecule that fits a pocket computationally is not automatically a good drug. Predicted binding must be supported by experimental validation, and properties such as toxicity, pharmacokinetics, and efficacy must be evaluated.

The bigger picture: By combining protein structures, computational chemistry, and generative AI, pocket-conditioned drug design offers a promising approach to structure-based drug discovery.

The goal is not just to generate molecules, but to generate meaningful candidates worth testing in the laboratory.

10/28/2026

3Di in protein structure analysis

Foldseek tool is used in searching and comparing protein structures.

What is 3Di?

3Di stands for a three-dimensional interaction structural alphabet. Foldseek converts information about the spatial relationships between amino acid residues in a protein structure into a sequence of 20 structural states. This allows researchers to search and compare protein structures rapidly. 

How it fits into drug discovery

Target identification:

• Explore structural similarities that may suggest relationships between proteins.

Structure-based drug design:

• Use protein structures to investigate binding pockets and guide downstream docking and molecular modeling.

One important distinction: 3Di does not itself predict a protein structure. It represents structural information so that protein structures can be searched and compared efficiently. To obtain predicted structures, researchers might use tools such as AlphaFold; Foldseek can then search those structures.

FoldSeek GitHub: https://github.com/steineggerlab/foldseek

Foldseek enables fast and sensitive comparisons of large structure sets. - steineggerlab/foldseek

10/28/2026

What Is a Pharmacophore? The Key to Understanding Drug–Target Interactions

How do scientists identify the essential features a molecule needs to interact with a biological target?

The answer often involves pharmacophore modeling.

A pharmacophore is the collection of essential steric and electronic features required for a molecule to interact with a specific biological target and produce or influence a biological response.

These features may include:

🔹 Hydrogen bond donors and acceptors - help form specific molecular interactions.

🔹 Hydrophobic regions - support interactions with nonpolar parts of a binding site.

🔹 Aromatic rings - can contribute to stacking and other molecular interactions.

🔹 Positive and negative ionizable features - support electrostatic interactions.

💡 Why does it matter in drug discovery?

Pharmacophore modeling can help researchers:

• Screen large chemical libraries for promising drug candidates.
• Identify essential molecular features associated with biological activity.
• Understand similarities between compounds with different chemical structures.
• Guide virtual screening and lead optimization.
• Support AI-driven drug discovery workflows.

Here is the key insight: Two molecules can have different chemical structures yet share similar pharmacophoric features and potentially interact with the same biological target.

However, a pharmacophore match does not guarantee binding, biological activity, safety, or therapeutic efficacy. Experimental validation remains essential.

As drug discovery increasingly integrates computational chemistry, structural biology, and artificial intelligence, pharmacophores remain valuable tools for connecting molecular structure with biological function.

In drug discovery, understanding the features a molecule needs can be just as important as understanding the molecule itself.

10/28/2026

💊 Drug Discovery vs. Drug Development: What’s the Difference?

Ever wondered how a scientific idea becomes a medicine that reaches patients?

Drug discovery is where the journey begins. Scientists identify biological targets, discover promising molecules, and optimize potential drug candidates to address a disease.

Drug development takes those promising candidates further. It involves preclinical testing, clinical trials, manufacturing, and regulatory review to determine whether a candidate can become a safe and effective treatment.

Think of it this way:

💡 Discovery asks: Can we find or design a molecule that works?

🏥 Development asks: Can we turn that molecule into a medicine that is safe, effective, manufacturable, and ready for patients?

For biotech startups, understanding this distinction is essential. A promising molecule is an important milestone, but translating that discovery into a medicine requires rigorous science, substantial investment, regulatory strategy, and perseverance.

At the intersection of AI and biotechnology, new approaches are creating opportunities to accelerate parts of both processes, but scientific validation remains critical.

The ultimate goal is not simply to discover molecules. It is to translate scientific breakthroughs into meaningful treatments for patients. 🧬